CEO Torsten Freltoft presents AcouSort's opportunities in cell therapy and diagnostics at LSX Nordic Congress on October 10

AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, analytics, and cell therapy processing markets. The company is in early commercial phase with continuously strengthened positions in the company's focus areas – diagnostics, cell therapy and innovation.

The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It has been connecting life science and healthcare industry leaders with international investment and strategic partners to further the growth, development and internationalization of Nordic life science and healthcare innovation since 2018. AcouSort’s presentation will take place during the Med/Health-tech Showcase steam on Tuesday 10th October at 16:30.

"I have presented AcouSort many times, but it has never been more stimulating to do so than now. The Company is in a very exciting phase with several interesting research and development collaborations with the potential to lead to OEM agreements where our unique technology is integrated into various systems for diagnostics and production of cells for cell therapies," says Torsten Freltoft, AcouSort’s CEO.

Register here: https://www.lsxleaders.com/lsx-nordic-congress